Abvc biopharma entered into a global licensing deal of vitargus with licensing income of $33.5m and royalties up to $60m

Fremont, ca, march 26, 2024 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that each of the company and its subsidiary biofirst corporation entered into a global licensing agreement with forseecon eye corporation (feye) for the company's ophthalmology pipeline, which includes the medical device vitargus® (valued at $187m, by third-party valuer) (the "licensed products"). this license will cover the licensed products' clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC Ratings Summary
ABVC Quant Ranking